The FDA amended its approval for Balversa for the treatment of patients with locally advanced or metastatic bladder cancer. The Food and Drug Administration (FDA) approved Balversa (erdafitinib) for ...

Some patients with metastatic bladder cancer and FGFR3 genetic alterations may benefit from Balversa, as it “represents a critical need,” an expert said. The recent approval of Balversa (erdafitinib) ...

Johnson & Johnson’s Balversa can keep some metastatic bladder cancer patients alive longer than chemotherapy, according to a study of 266 who have fibroblast growth factor receptor (FGFR) gene ...

Targeted therapies that aim at specific genetic biomarkers have been widely adopted in several cancer types, but not in bladder cancer. But a new nod the FDA doled out Friday could change that—and ...

New York, USA, March 04, 2025 (GLOBE NEWSWIRE) -- BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight BALVERSA (erdafitinib) has strong market potential in ...

Johnson & Johnson JNJ announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), ...

Johnson & Johnson’s (J&J) Balversa (erdafitinib) has been granted approval by the European Commission (EC) to treat a subset of bladder cancer patients. The pan-fibroblast growth factor receptor (FGFR ...

DUBLIN--(BUSINESS WIRE)--The "Balversa - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Balversa - Drug Insight, 2019 report provides comprehensive information of the ...

Friday afternoon, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application (sNDA) for Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial ...

10 urothelial cancer patients in Scotland are anticipated to receive this treatment per year [i] High Wycombe, UK (12 May 2025) – Johnson & Johnson is delighted to announce that BALVERSA® (erdafitinib ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...

The FDA today granted accelerated approval to erdafitinib for the treatment of adults with locally advanced or metastatic bladder cancer that progressed during or following platinum-containing ...